Raggi Paolo, Cooil Bruce, Ratti Carlo, Callister Tracy Q, Budoff Matthew
Tulane University School of Medicine, 1430 Tulane Ave, SL-48, New Orleans, LA 70112, USA.
Hypertension. 2005 Jul;46(1):238-43. doi: 10.1161/01.HYP.0000164575.16609.02. Epub 2005 Apr 25.
Progression of coronary artery calcium, a marker of atherosclerosis, can be slowed with statins, and continued progression of calcium is associated with an increased risk of myocardial infarction. However, it is not known whether statins are effective in slowing calcium progression in diabetes mellitus. In a retrospective study, we examined 1153 nondiabetic and 157 diabetic subjects who underwent sequential electron beam tomography scans at a minimum 1-year interval to assess progression of coronary calcium. A yearly score increase >15% was considered evidence of true progression. The use of statins and occurrence of myocardial infarction were recorded. There was no difference in baseline calcium score between diabetic and nondiabetic patients. Diabetic patients with no coronary calcium on the baseline scans developed it more often than nondiabetic subjects (42% versus 25%; P=0.046) during follow-up. Calcium progression was 33% greater in diabetic patients than nondiabetic subjects (P<0.001) if no statin therapy was provided and 17.7% greater when statins were used (P<0.001). Among the 49 subjects who experienced a myocardial infarction, the calcium score increased on average 20% more in diabetic than nondiabetic patients (P<0.001). In logistic models, diabetes mellitus and systemic hypertension were the best predictors of calcium progression (odds ratio, 3.1 and 1.9, respectively), whereas baseline calcium score percentile and statin therapy were the best predictors of infarction. These findings support the notion that diabetes mellitus causes accelerated atherosclerosis, even in the presence of statin therapy, and provide evidence that coronary calcium monitoring is an effective method to assess treatment efficacy.
冠状动脉钙化是动脉粥样硬化的一个标志物,他汀类药物可减缓其进展,而钙化的持续进展与心肌梗死风险增加相关。然而,尚不清楚他汀类药物在减缓糖尿病患者冠状动脉钙化进展方面是否有效。在一项回顾性研究中,我们检查了1153名非糖尿病患者和157名糖尿病患者,这些患者至少间隔1年接受了连续的电子束断层扫描,以评估冠状动脉钙化的进展情况。每年评分增加>15%被视为真正进展的证据。记录他汀类药物的使用情况和心肌梗死的发生情况。糖尿病患者和非糖尿病患者的基线钙化评分没有差异。基线扫描时无冠状动脉钙化的糖尿病患者在随访期间比非糖尿病患者更常出现钙化(42%对25%;P=0.046)。如果不进行他汀类药物治疗,糖尿病患者的钙化进展比非糖尿病患者高33%(P<0.001),使用他汀类药物时高17.7%(P<0.001)。在49名发生心肌梗死的患者中,糖尿病患者的钙化评分平均比非糖尿病患者增加20%(P<0.001)。在逻辑模型中,糖尿病和系统性高血压是钙化进展的最佳预测因素(优势比分别为3.1和1.9),而基线钙化评分百分位数和他汀类药物治疗是梗死的最佳预测因素。这些发现支持了这样一种观点,即即使在使用他汀类药物治疗的情况下,糖尿病也会导致动脉粥样硬化加速,并提供了证据表明冠状动脉钙化监测是评估治疗效果的有效方法。